LEPU BIO-B (02157) announced that the National Medical Products Administration (NMPA) has recently approved the market application of its self-developed candidate drug Meiyouheng® (Vebecotuzumab Injection) in China. The drug is an innovative epidermal growth factor receptor (EGFR)-targeting antibody-drug conjugate (ADC) for the treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M NPC). Meiyouheng® (Vebecotuzumab Injection) is the first approved EGFR-targeting ADC in China, marking a pioneering achievement in its class. The approval of Meiyouheng® represents another significant milestone for the company, as its launch for R/M NPC treatment is expected to improve patient outcomes. LEPU BIO-B also plans to expand the drug's indications based on this approval to accelerate the realization of its potential commercial value.